Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc generates news typical of clinical-stage biotechnology companies developing novel therapeutics. Investors following AZTR track announcements related to clinical trial milestones, regulatory developments, scientific presentations, and capital raising activities—the key events that drive valuation for pre-revenue pharmaceutical companies.
Clinical development updates represent the most significant news category for biotechnology stocks. Patient enrollment milestones, safety data releases, efficacy readouts, and regulatory submissions directly impact the probability that drug candidates will achieve approval and eventual commercialization. For Azitra's microbiome-based dermatology programs, news about trial design, patient populations, and preliminary results provides insight into whether the company's scientific approach translates into measurable therapeutic benefits.
Financing announcements constitute another critical news category. Clinical trials require substantial capital, making funding transactions essential for maintaining development timelines. News about equity offerings, partnership deals, grant awards, or other capital sources reveals both the company's financial health and market confidence in its development programs. Changes in share structure, including reverse stock splits or warrant exercises, also generate material disclosures that affect shareholder value.
Scientific conference presentations and publications offer windows into development progress between formal trial readouts. When company scientists present data at dermatology or microbiome research conferences, these forums provide technical details about therapeutic mechanisms, preclinical findings, and early clinical observations. While less definitive than full trial results, conference abstracts and posters signal how the scientific community receives the company's research approach and whether academic experts view the platform as scientifically credible.
Regulatory interactions generate newsworthy events as companies navigate FDA review processes. Orphan drug designations, fast track status, study design agreements, and regulatory feedback shape development timelines and approval probabilities. For investors assessing Azitra's prospects, understanding the regulatory pathway for live biotherapeutic products—a relatively novel therapeutic category—provides context for evaluating development risk and potential approval timelines.
Azitra (NYSE: AZTR) reported its full year 2024 financial results and business updates. The company initiated a Phase 1b trial for ATR-12 in Netherton syndrome patients, with initial safety data expected in H1 2025 and topline data by year-end 2025. The FDA cleared a Phase 1/2 study of ATR-04 for EGFRi-associated dermal toxicity and granted it Fast Track designation.
Financial highlights include: service revenue of $0.8K (down from $0.7M in 2023), R&D expenses of $4.7M (up from $3.6M), G&A expenses of $6.3M (up from $4.5M), and a net loss of $9.0M (improved from $11.3M in 2023). Cash position stood at $4.6M as of December 31, 2024, with additional $2.2M raised in early 2025.
The company completed public offerings totaling $15M and strengthened its IP portfolio. ATR-04 targets a market opportunity exceeding $1B, affecting approximately 150,000 US patients annually.
Azitra (NYSE American: AZTR) has announced a registered direct offering of 3,339,300 shares of common stock priced at $0.2785 per share, expected to raise approximately $930,000 in gross proceeds. The offering, scheduled to close on February 5, 2025, is being conducted with institutional investors through a securities purchase agreement.
The company plans to use the net proceeds for working capital and general corporate purposes. Maxim Group is serving as the sole placement agent for the offering, which is being made under an effective shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and declared effective on July 8, 2024.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in the upcoming BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, in New York City.
The company's presentation is scheduled for February 10, 2025, at 3:45 p.m. ET in the Royale Room at The New York Marriott Marquis. Travis Whitfill, Chief Operating Officer, will lead the presentation.
During the conference, Azitra's management team will engage in one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing the company's business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in The Microcap Conference 2025. The presentation is scheduled for January 29, 2025, at 11:00 a.m. ET at the Borgata Hotel Casino & Spa in Atlantic City, NJ.
Chief Executive Officer Francisco Salva will lead the presentation in Studio C. During the conference, which runs from January 28-30, 2025, the company's management team will engage in one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the pricing of its public offering of 4,857,780 shares of common stock at $0.30 per share. The offering is expected to generate gross proceeds of approximately $1.5 million before deducting placement agent fees and other expenses.
The offering is scheduled to close on January 16, 2025, subject to customary conditions. The company plans to use the net proceeds for working capital and general corporate purposes. Maxim Group is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the commencement of a public offering of common stock and pre-funded warrants. Maxim Group will serve as the sole placement agent for the offering.
The company plans to utilize the net proceeds for working capital and general corporate purposes. The offering is being conducted through an effective shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and declared effective on July 8, 2024. The completion, size, and terms of the offering are subject to market conditions and cannot be guaranteed.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in Biotech Showcase 2025. The event will take place from January 13-15, 2025 in San Francisco, with Azitra's presentation scheduled for January 13 at 3:00 p.m. PT at the Hilton San Francisco Union Square.
Chief Operating Officer Travis Whitfill will lead the presentation, and the company's management team will conduct one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business strategy, clinical development plans, recent achievements, and future milestones.
The Biotech Showcase, organized by Demy-Colton and EBD Group, serves as a leading investor conference for private and micro-mid-cap biotechnology companies to present their innovations and connect with investors.
Azitra (AZTR) reported Q3 2024 financial results and business updates. Key highlights include completing a $10 million follow-on offering, dosing the first Netherton syndrome patient with ATR-12, and receiving FDA Fast Track designation for ATR-04. Financial results show zero service revenue compared to $310,700 in Q3 2023, R&D expenses of $1.0 million (up from $0.5 million), and G&A expenses of $1.9 million. The company reported a net loss of $1.0 million and held cash and equivalents of $7.3 million as of September 30, 2024. Upcoming milestones include initial safety data and first patient dosing for key trials in Q1 2025.
Azitra (NYSE American: AZTR) announces its participation at BIO-Europe 2024 in Stockholm, Sweden, scheduled for Monday, November 4, 2024, at 2:30pm CET. Travis Whitfill, Chief Operating Officer, will deliver a corporate presentation highlighting the company's pipeline progress, particularly focusing on two key developments: ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-induced dermal toxicity.
The company reports significant achievements in 2024, including the first patient dosing with ATR-12 and receiving FDA Fast Track designation for ATR-04. The presentation will take place at Stockholmsmässan, with opportunities for one-on-one meetings through the BIO One-on-One Partnering system.
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has been invited to present at the 2024 Maxim Healthcare Virtual Summit. The event, hosted by Maxim Group , will take place from October 15-17, 2024.
Azitra's Chief Operating Officer, Travis Whitfill, will participate in a panel presentation on Thursday, October 17, 2024, at 2:00 p.m. ET. The presentation will be part of the rare disease panel, featuring Azitra alongside other companies such as Quoin Pharmaceuticals, Rezolute, and Zevra Therapeutics.
The summit will showcase a range of biotechnology, diagnostic, medical device, and healthcare information technology companies. Maxim Senior Analysts will host interactive discussions with CEOs and key management, providing insights into various healthcare sectors.
FAQ
What is the current stock price of Azitra (AZTR)?
What is the market cap of Azitra (AZTR)?
